Compare CBNK & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBNK | DCTH |
|---|---|---|
| Founded | 1974 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.3M | 578.4M |
| IPO Year | 2018 | 2015 |
| Metric | CBNK | DCTH |
|---|---|---|
| Price | $42.10 | $21.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $44.08 | $26.60 |
| AVG Volume (30 Days) | 136.9K | ★ 424.9K |
| Earning Date | 10-26-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | 60.85 | ★ 107.53 |
| EPS | ★ 2.40 | 0.21 |
| Revenue | N/A | N/A |
| Revenue This Year | $8.98 | $36.96 |
| Revenue Next Year | $10.68 | $18.85 |
| P/E Ratio | ★ $17.82 | $499.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.40 | $8.12 |
| 52 Week High | $44.76 | $20.03 |
| Indicator | CBNK | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 58.96 | 82.16 |
| Support Level | $35.70 | $10.76 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.94 | 0.84 |
| MACD | -0.05 | 0.72 |
| Stochastic Oscillator | 40.77 | 97.79 |
Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage. The company generates majority revenue from the Commercial bank sector. Commercial Banking division focuses on providing personalized service to commercial clients throughout the operations supplemented by lending outside primary market as well as engaging in government guaranteed lending on a national basis.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.